GlassScriptPhysician profile
Adam Miller
NPI 1831366897
$12,676.27
in general payments reported to CMS, 2019-2025
20 companies · $4,146 in 2025
The $4,146 reported for 2025 was more than what a typical Foot and Ankle Surgery provider received nationally (typical 2025 total: $1,200).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $132 · 2021: $3,730 · 2022: $699 · 2023: $2,882 · 2024: $501 · 2025: $4,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $5,675 · Food and Beverage: $1,181 · Travel and Lodging: $672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $5,675.15 |
| Food and Beverage | $1,181.22 |
| Travel and Lodging | $672.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Solutions INC | $6,083.18 | 2019-2025 | |
| Legacy Ortho LLC | $4,202.26 | 2021-2025 | |
| Stryker Corporation | $753.14 | 2022-2025 | Ortholoc 3di Crosscheck, Mako |
| Depuy Synthes Sales INC. | $211.27 | 2022-2023 | Truespan Orthocord, Na, Dynacord |
| Arthrex, INC. | $209.21 | 2021-2025 | |
| Onkos Surgical, INC. | $153.18 | 2025 | Eleos Limb Salvage System |
| Bioventus LLC | $146.87 | 2024 | Exogen Ultrasound Bone Healing System |
| Orthofix Medical, INC. | $142.86 | 2023 | Truelok |
| Wright Medical Technology, INC. | $125.00 | 2019 | |
| Biotissue Holdings INC. | $124.65 | 2024 | |
| Integra Lifesciences Corporation | $113.86 | 2019 | |
| Intersect Ent, INC. | $76.08 | 2019 | |
| Medtronic, INC. | $74.27 | 2024 | Shilla Growth Guidance System |
| Smith+Nephew, INC. | $60.76 | 2021-2023 | Evos, Cadence |
| Zimmer Biomet Holdings, INC. | $60.09 | 2024-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $49.12 | 2025 | Winrevair |
| Ferring Pharmaceuticals INC. | $31.09 | 2021 | |
| Gilead Sciences, INC. | $26.52 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $19.85 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $13.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.